Back to search

Article

High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis – real-world data of HCV elimination program in Georgia

2019-12-09

Abstract excerpt

<h4>Background: </h4> In 2015, Georgia launched world’s first HCV elimination program. Initially, patients with advanced liver disease were prioritized to receive sofosbuvir-based treatment regimen, as it was the only DAA available for all genotypes. Purpose of the study was to assess real-world data of treatment outcome among patients with HCV GEN3 and advanced liver fibrosis with sofosbuvir-based regimens. <h4>M...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3cf43a17-372c-5ab2-968a-0bca2a49a4c8
DOI
10.21203/rs.2.18492/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis – real-world data of HCV elimination program in GeorgiaDOI 10.21203/rs.2.18492/v1
High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia.Semantic proximity
Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.Semantic proximity
Chronic Hepatitis C and comorbidities: real-world study to evaluate impact in outcomes after treatment with sofosbuvir-based regimensSemantic proximity
Sofosbuvir-based therapies achieved satisfactory virological response in Chinese with genotypes&nbsp;3 and 6 infection:&nbsp;a real-world experience from a centreSemantic proximity
Interim impact evaluation of the hepatitis C virus elimination program in GeorgiaSemantic proximity
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.Semantic proximity
Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.Semantic proximity
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.Semantic proximity
Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics.Semantic proximity
Genotype 3-hepatitis C virus' last line of defense.Semantic proximity
Sofosbuvir/Velpatasvir plus Ribavirin for chronic hepatitis C virus genotype 3 infected cirrhotic patients with or without HIV or HBV coinfection: Real-world experience from Southwest ChinaSemantic proximity
A Multi-Biomarker Prediction Model Integrating Genetics, Hematological Indices, and Fibrosis Stage to Forecast Non-Response in HCV Genotype 4Semantic proximity
Select a neighboring publication to make it the new centre.